Prosecution Insights
Last updated: November 08, 2026
Application No. 19/406,609

Vessel Morphology Radiomic Phenotypes

Non-Final OA §112
Filed
Dec 02, 2025
Priority
Dec 03, 2024 — provisional 63/727,570 +4 more
Examiner
HU, ANN M
Art Unit
3774
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Picture Health Inc.
OA Round
2 (Non-Final)
68%
Grant Probability
Favorable
2-3
OA Rounds
2y 9m
Est. Remaining
89%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
651 granted / 961 resolved
-2.3% vs TC avg
Strong +22% interview lift
Without
With
+21.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
50 currently pending
Career history
1023
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
48.0%
+8.0% vs TC avg
§102
26.9%
-13.1% vs TC avg
§112
17.9%
-22.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 961 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments Applicant’s arguments with respect to claim(s) 1-13, 25, and 28-30 have been considered, but are moot in view of the new grounds of rejection. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 1 and its dependent claims are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Amended claim 1 states that the phenotypical set of radiomic vessel morphology features being (1) at least a subset of the set of radiomic vessel morphology features extracted from the first medical images, and (2) characteristic of the two or more groups. It is unclear what is intended to be claimed by language of the phenotypical set of radiomic vessel morphology features being “characteristic of the two or more groups.” Claim 1 and its dependent claims are also rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The disclosure does not appear to have adequate support for the recitation of the phenotypical set of radiomic vessel morphology features being (1) at least a subset of the set of radiomic vessel morphology features extracted from the first medical images, and (2) characteristic of the two or more groups. Appropriate correction is required. Claim 1 also recites a broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 1 recites the broad recitation “the phenotypical set of radiomic vessel morphology features being (1) at least a subset of the set of radiomic vessel morphology features extracted from the first medical images, and (2) characteristic of the two or more groups;” and the claim also recites “the phenotypical set of radiomic vessel morphology features describe one or more of a physical form of blood vessels, organization of groups of the blood vessels, or mechanical properties of the blood vessels,” which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. It is also unclear what constitutes the subset of the set of radiomic vessel morphology features, when both the set of radiomic vessel morphology features and the phenotypical set of radiomic vessel morphology features are described as the same features of one or more of a physical form of blood vessels, organization of groups of the blood vessels, or mechanical properties of the blood vessels. As presently worded, the metes and bounds of the claims cannot be properly established. Appropriate correction is required. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ann Hu whose telephone number is (571) 272-6652. The examiner can normally be reached on Monday-Friday (9:00 am-5:30 pm EST). If attempts to reach the examiner by telephone are unsuccessful, please contact the examiner’s supervisor, Jerrah Edwards, at (408) 918-7557. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ANN HU/Primary Examiner, Art Unit 3774
Read full office action

Prosecution Timeline

Dec 02, 2025
Application Filed
Jun 17, 2026
Non-Final Rejection mailed — §112
Jun 30, 2026
Examiner Interview Summary
Jun 30, 2026
Applicant Interview (Telephonic)
Sep 10, 2026
Response Filed
Oct 02, 2026
Final Rejection mailed — §112
Oct 07, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778738
GRAFT FOR BIOLOGICAL TUBE AND SYSTEM THEREOF
3y 8m to grant Granted Nov 03, 2026
Patent 12765998
EXTERIORLY MOUNTED TISSUE ON EXPANDABLE FRAME FOR IMPROVED HEMODYNAMIC PERFORMANCE
3y 9m to grant Granted Oct 20, 2026
Patent 12758402
DEVICE AND METHOD FOR ACQUIRING DIGITIZED IMPRESSIONS IN ORDER TO GENERATE A 3D MODEL OF A SOCKET FOR AN ABOVE-KNEE PROSTHESIS
2y 10m to grant Granted Oct 13, 2026
Patent 12755410
SYSTEMS AND METHODS FOR AN ENVIRONMENT-AWARE PREDICTIVE MODELING FRAMEWORK FOR HUMAN-ROBOT SYMBIOTIC WALKING
2y 9m to grant Granted Oct 06, 2026
Patent 12746120
CONTROLLABLY DEPLOYABLE PROSTHETIC VALVE
3y 7m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
68%
Grant Probability
89%
With Interview (+21.6%)
3y 9m (~2y 9m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 961 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month